TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06751953

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional third-line therapy
Description: Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-loaded DC vaccine
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06752590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1110
Description: ONO-1110 tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study: NCT06755593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: We use acupuncture needles of size 0.30 \* 25 mm and electroacupuncture machine KWD808-1 manufactured by Gujin Greatwall (Frequency 100Hz)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: We use acupuncture needles of size 0.30 \* 25 mm and electroacupuncture machine KWD808-1 manufactured by Gujin Greatwall (Frequency 100Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous laser
Description: We use intravenous laser with the iBIO-ILIB He-Ne laser device Mini-630 with 635 nm wavelength manufactured by Vietnam Laser Technology Center.
Study: NCT06755762

Intervention type: OTHER
Intervention: Organoid 3D culture
Description: Investigate different normal cells (lung, bone, soft tissue, liver, etc) as metastatic organs to simulate the behaviors of CTCs in metastatic sites

Intervention type: OTHER
Intervention: Organoid 3D culture
Description: Investigate different normal cells (lung, bone, soft tissue, liver, etc) as metastatic organs to simulate the behaviors of CTCs in metastatic sites
Study: NCT06754657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous perineural infusion
Description: infusion rate 4 ml/h, with 5 ml boluses (30-minute lockout). The PCA button disabled

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single injection
Description: infusion rate 0 ml/h, with 5 ml boluses (30-minute lockout). The PCA button will be enabled for rescue bolus administration
Study: NCT06755307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMNiBiOTiC® Panda
Description: Multistrain Probiotic OMNiBiOTiC® Panda containing: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactococcus lactis W58 and sunflower oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing sunflower oil and maltodextrin
Study: NCT06753513

Intervention type: OTHER
Intervention: 99mTc-FDPH46 SPECT/CT Imaging
Description: 99mTc-FDPH46 SPECT/CT Imaging
Study: NCT06753812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: constraint induced movement therapy
Description: Children in this group will receive constraint induced movement therapy for 10 sessions over 2 weeks, each session lasting 90 minutes, in addition to the treatment they receive 2 days a week at the special education and rehabilitation centers they attend.

Intervention type: OTHER
Group type: OTHER
Intervention: Control (Standard treatment)
Description: Children in this group will continue to receive their treatment at the special education and rehabilitation center they attend, two days a week for 40 minutes.
Study: NCT06751901

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-based peptide vaccine
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06752512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: 24/7 remote patient monitoring with a wearable thermometer
Study: NCT06754306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal diet (100% energy)
Description: Daily intake of 100% energy requirements, adjusted individually based on each participant's basal metabolic rate (BMR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16+8 time-restricted eating group (100% energy)
Description: Participants will consume 100% energy within an 8-hour eating window and fast for the remaining 16 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16+8 time-restricted eating group (75% energy)
Description: Participants will consume 75% of their energy requirements within the 8-hour eating window.
Study: NCT02860559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBX-1400
Description: Hematopoietic stem cells transplantation
Study: NCT05159778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
Study: NCT05173259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the two-coloured chewing gum naturally.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the two-coloured chewing gum naturally.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the two-coloured chewing gum naturally.
Study: NCT06754306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting group (75% energy)
Description: Participants alternate between feeding days (125% energy requirements) and fasting days (25% energy requirements).
Study: NCT05173259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the two-coloured chewing gum naturally.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the two-coloured chewing gum naturally.
Study: NCT06754306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5+2 intermittent fasting group (75% energy)
Description: Participants consume 95% energy requirements for 5 consecutive days and 25% energy requirements for 2 fasting days.
Study: NCT05173259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the two-coloured chewing gum naturally.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the two-coloured chewing gum on the right-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the two-coloured chewing gum on the right-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the two-coloured chewing gum on the right-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the two-coloured chewing gum on the right-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the two-coloured chewing gum on the right-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the two-coloured chewing gum on the right-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the two-coloured chewing gum on the left-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the two-coloured chewing gum on the left-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the two-coloured chewing gum on the left-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the two-coloured chewing gum on the left-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the two-coloured chewing gum on the left-side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the two-coloured chewing gum on the left-side.
Study: NCT06754306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-calorie diet group (75% energy)
Description: Participants will reduce daily caloric intake to 75% of energy requirements, consumed evenly across three meals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low-calorie diet group (45% energy)
Description: Participants will reduce daily caloric intake to 45% of energy requirements (\~800 kcal/day)
Study: NCT06753552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Underwater US
Description: 7 min per session with an intensity of 0.9 W/cm2 for 20 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Underwater US
Description: 7 min per session with an intensity of 0.9 W/cm2 for 20 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CFO
Description: Custom made orthotics
Study: NCT06295952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-36 and HADS
Description: Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
Study: NCT06755801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevibolol
Description: Beta-blockers are the first-line treatment for patients with stable angina secondary to classic epicardial atherosclerotic disease, where their clinical benefits are well-established (4). However, their efficacy has not yet been demonstrated in ANOCA patients with MVD, where beta-blockers are frequently used due to their physiological plausibility. Beta-blockers act by competitively inhibiting catecholamine receptors. The therapeutic benefits of beta-blockade in patients with stable angina are mediated by a reduction in myocardial oxygen demand. Myocardial oxygen demand depends on heart rate, contractility, and left ventricular wall tension, all of which are reduced with beta-adrenergic blockade. The reduction in wall tension is partly mediated by the antihypertensive action of these drugs. The decrease in heart rate occurs both at rest and during sympathetic activation such as exercise or stress. The negative inotropic effect of these drugs also contributes to reducing myocardial oxyg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06754358

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LenSx
Description: Participants undergo FLACS using LenSx femtosecond laser system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Z8
Description: Participants undergo FLACS using Z8 femtosecond laser system
Study: NCT05757219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR) T-cell therapy
Description: Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
Study: NCT04514341

Intervention type: OTHER
Intervention: Short Message Service (SMS)
Description: Patients with FIT orders receive seven messages over 60 days to remind them to return their kits for testing. Patients with colonoscopy orders receive eight messages to remind them to schedule an appointment for a colonoscopy over 90 days. After confirming their colonoscopy appointment, the patient gets educational messages on bowel preparation.

Intervention type: OTHER
Intervention: Remote Patient Navigation
Description: Patient navigators at our partner FQHCs called patients who received a screening order for more than 60 days but failed to complete it or who had a positive stool-based test and needed a follow-up diagnostic colonoscopy.
Study: NCT04573881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HistoSonics System
Description: The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
Study: NCT06431503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tok-Sen Massage
Description: Press the wedge and tapping: the strength for pressing the wedge is 1000g±50g, the height for mallet free fall(instead of beating by arm)10cm±2cm. For Pressure massage, the strength for pressing the wedge is 1500g±50g.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Massage
Description: Press the wedge: the strength for pressing the wedge is 1500g±50g,
Study: NCT05696899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents
Description: A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
Study: NCT04729816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.
Description: Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63
Study: NCT06495853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Circumferential Reinforcement of the Anastomotic
Description: The reinforcement began on the right side of the anterior wall of the anastomosis, 0.5 cm from the anastomotic line, with continuous full-thickness sutures spaced 1 cm apart. The suture ended with fixation of the suture tail using non-absorbable vascular clips. The decision to perform splenic flexure mobilization depended on the anastomotic tension and the length of the resected bowel segment. The superior mesenteric artery and vein were divided at their roots.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Circumferential Reinforcement of the Anastomotic
Description: The reinforcement began on the right side of the anterior wall of the anastomosis, 0.5 cm from the anastomotic line, with continuous full-thickness sutures spaced 1 cm apart. The suture ended with fixation of the suture tail using non-absorbable vascular clips. The decision to perform splenic flexure mobilization depended on the anastomotic tension and the length of the resected bowel segment. The superior mesenteric artery and vein were divided at their roots.
Study: NCT05390840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-O-1002
Description: MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MG-O-1002
Description: MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is 0.9% saline ocular administration 3 drops in study eye
Study: NCT05703568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: 14 elderly participants receive intervention protocol of group- based virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 14 elderly participants receive intervention protocol of individual virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
Study: NCT04341701

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent
Study: NCT06443775

Intervention type: DRUG
Intervention: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Description: Eye Drops
Study: NCT06536127

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Nk cells and ImmunoScore
Study: NCT05750290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-702 in combination with irinotecan
Description: CKD-702 and irinotecan will be intravenously administered every 2 weeks.
Study: NCT06023329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: will receive SCPB with ropivacaine via regional anesthesia team

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: will receive SCPB with saline via regional anesthesia team
Study: NCT05786248

Intervention type: OTHER
Group type: OTHER
Intervention: Impedancemetry
Description: the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
Study: NCT04947462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronically Implanted Neural and Muscular Interface
Description: Participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
Study: NCT06423846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia group
Description: Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol. 200 ug/kg/min, fentanyl 0.1ug/kg/min, dexmedetomidine 1 ug/kg/hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane group
Description: For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
Study: NCT05620875

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral injury markers
Description: Blood tests at given time points perioperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral injury markers
Description: Blood tests at given time points perioperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral oximetry index
Description: Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral oximetry index
Description: Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy
Study: NCT05895461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWLI-College
Description: Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant.
Study: NCT06575829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks
Description: The interval of ERT with alglucosidase alfa will be extended from once every 2 weeks to once every 4 weeks. The dose of 20 mg/kg per infusion remains the same.
Study: NCT05895461

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Psychoeducation around dieting myths, healthy eating, and physical activity